Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291517 | 0.97 | BRD9 (0.55) | BRD9CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL23729480 | 0.86 | CRBN (0.64) | BRD9CRBNDDB1IKZF2STAT3 | |
| Formic Acid SCHEMBL29794421 | 0.85 | CRBN (0.52) | BRD9CRBNDDB1STAT3 | |
| SCHEMBL30893191 | 0.84 | CRBN (0.55) | BRD9CRBNDDB1STAT3 | |
| SCHEMBL25102531 | 0.84 | CRBN (0.50) | BRD9CRBNDDB1IKZF2IKZF1 | |
| Formic Acid SCHEMBL29794438 | 0.83 | CRBN (0.51) | BRD9CRBNDDB1STAT3 | |
| SCHEMBL23705705 | 0.83 | CRBN (0.46) | BRD9CRBNDDB1IKZF2IKZF1 | |
| Hydrochloric Acid SCHEMBL30893274 | 0.83 | CRBN (0.54) | BRD9CRBNDDB1STAT3 | |
| Hydrochloric Acid SCHEMBL30893267 | 0.83 | CRBN (0.54) | BRD9CRBNDDB1STAT3 | |
| Hydrochloric Acid SCHEMBL30893302 | 0.83 | CRBN (0.54) | BRD9CRBNDDB1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | BRD9 578/4885CRBN 163/4885DDB1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.